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Abstract
Purpose: To assess the diagnostic value of O-2-fluoro-18(F)-ethyl-L-tyrosine (18F-FET) positron
emission tomography/computed tomography (PET/CT) for patients with advanced head and
neck squamous cell carcinoma compared with 18F-fluoro-2-deoxy-D-glucose (18F-FDG) PET/CT
at initial staging and following radiochemotherapy.
Procedures: Thirteen patients were prospectively enrolled; each of them underwent an 18F-FDG
PET/CT and 18F-FET PET/CT before treatment. Ten of those were scanned 10 weeks after
treatment.
Results: Sensitivity, specificity, and accuracy for 18F-FDG PET/CT (primary and lymph node
metastases) at initial staging were 89%, 50%, and 81%. For 18F-FET PET/CT the numbers were
70%, 90%, and 74%. Sensitivity, specificity, and accuracy for 18F-FDG PET/CT at follow-up
were 71%, 65%, and 67%. For 18F-FET PET/CT the numbers were 29%, 100%, and 83%.
Additionally, 18F-FDG PET/CT detected a higher number of second malignancies or distant
metastases.
Conclusions: 18F-FET is no substitute for 18F-FDG. Although it is more specific, too many
malignant lesions are missed due to its lower sensitivity.
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Introduction
The clinical value of 2-deoxy-2-[
18F]fluoro-D-glucose
positron emission tomography/computed tomography
(18F-FDG PET/CT) in primary staging of head and neck
squamous cell carcinoma (HNSCC) is well documented [1].
Unfortunately, 18F-FDG also accumulates in inflammatory
tissue, which may cause false-positive results and therefore
the specificity for malignancies is decreased, in particular
after treatment by radiotherapy [2]. As a result of this,
radiolabelled amino acids were attracting increasing interest
in nuclear medicine over the past years. Amino acids are
specifically accumulated in malignant cells owing to
increased expression of amino acid transporters. In contrast
to glucose derivates, the uptake of amino acids in macro-
phages and other inflammatory cells is absent or at least
reduced [3, 4], therefore the amino acid tracers appear to be
more specific for tumor than FDG. Promising results for the
detection of HNSCC have been reported using L-methyl-
[11C]-methionine [5] and L-[1-(11) C]-tyrosine [3] as a
tracer. The drawback is the short physical half-life (20 min)
of the 11C label. On the contrary, 18F-labelled amino acid
analogues, such as O-(2-[18F]fluoroethyl)-L-tyrosine (18F-
FET), are logistically advantageous. Regarding the fact that
inflammatory tissue and lymph nodes are often present inCorrespondence to: Stephan Haerle; e-mail: Stephan.haerle@usz.ch
patients with HNSCC the rate of false-positive results by
18F-FDG PET is considerable. Previous studies describing
18F-FET as a potential tracer in HNSCC were first evaluat-
ing its value for initial staging [6]. According to the
disappointing results compared with 18F-FDG, later studies
investigated 18F-FET in the follow-up setting [7, 8]. The aim
of this prospective study was, for the first time, to assess the
diagnostic value of 18F-FET PET/CT in a cohort of patients
with advanced HNSCC compared with 18F-FDG PET/CT at
the time of initial staging and following radiochemotherapy
in the same patients, resulting in an intra-individual
comparison of the two modalities.
Materials and Methods
Patients
A total of 13 patients from the Department of Otorhinolaryngology,
Head and Neck Surgery at a tertiary referral center have been
enrolled in this prospective study between June 2008 and June
2009. This patient cohort does not represent a consecutive group of
all patients diagnosed with a HNSCC within the given time frame,
because mainly patients with advanced disease (T3/4, N2/3) were
referred to 18F-FDG PET/CT for search for potential distant
metastases. All of the patients were suffering from a previously
untreated HNSCC and all of the patients were staged by undergoing
panendoscopy, ultrasound-guided fine needle aspiration cytology
(USgFNAC) of the neck and biopsy of the primary. It is the
institutional policy that all the patients suffering from HNSCC are
primarly staged by USgFNAC as a first line examination. In our
experience, it is one of the most accurate methods for staging the
neck. In ten patients, the primary was located in the oropharynx,
whereas two patients were suffering from SCC of the oral cavity,
and one patient presented with a poorly differentiated SCC of the
nasopharynx. Further tumor characteristics are listed in Table 1.
Each of the 13 patients was examined with 18F-FDG PET/CT and
18F-FET PET/CT, before treatment. The order of the PET/CTs was
arbitrary. The interval between the two imaging modalities was not
longer than 2 weeks. Ten of those were again scanned 10 weeks after
treatment. The initial PET imaging was done before panendoscopy.
No therapy between the two imaging modalities was done. In the
patients which had a contrast-enhanced CT orMRI before the PET-CT
scan, the CT part of the PET-CT scan was done without contrast.
Radiochemotherapy consisted of intensity-modulated radiotherapy
(IMRT) and simultaneous systemic treatment was performed with
cisplatin (40 mg/m2 per week) or cetuximab (standard dosage). This
study was approved by university ethics committee. All subjects gave
written informed consent for participation in this prospective study.
Positron Emission Tomography Imaging
For this study, we used a combined PET/CT system (Discovery LS,
RX or Discovery STE, GE Health Systems, Milwaukee, WI). This
device integrates a PET scanner with a multi-slice helical CT and
permits the acquisition of coregistered CT and PET images in the
same session. Patients were examined in supine position.
Immediately following the low-dose CT acquisition (FOV
50 cm, auto mA, 120 kV, slice-thickness 3.75 mm, 0.5 s rotation
time, standard reconstruction type), 3D-PET emission data were
acquired for 1.5 and 2 min/bed position, respectively. The CT data
were used for attenuation correction and images were reconstructed
using a fully 3D iterative algorithm (VUE Point HD). The CT scan
was acquired during breath holding in the normal expiratory
position. The PET/CT scans were started 45 min following
injection of 350 MBq 18F-FDG, and, in accordance to a previous
report by Pauleit D et al. [7], 60 min after the application of
250 MBq 18F-FET.
The acquired images were post-processed with a dedicated
software (Volume Viewer PET/CT, AW 4.4 workstation, GE
Healthcare) providing multiplanar reformatted images of PET alone,
CT alone and fused PET/CT with linked cursors. At our institution,
blood glucose is checked in every patient before the 18F-FDG
injection. In this study, no patient suffered from hyperglycemia.
Standard of Reference and Data Analysis
The 18F-FDG- and 18F-FET PET/CT scans were evaluated by two
physicians, board certified in radiology and nuclear medicine and
both with years of PET/CT experience. Each read either the 18F-
FET or the 18F-FDG scan without access to the other scan. The
results from panendoscopy and cytological/histological work-up
were not available for the nuclear medicine specialists. The primary
tumor and suspicious lymph nodes were identified on CT or on the
PET scan. The standard of reference was the biopsy of the primary,
and the fine needle aspiration cytology of all the suspicious cervical
lymph nodes. As all the patients underwent USgFNAC before and
after treatment, a false-negative finding in the PET/CT scans is
defined as missed lymphatic disease in 18F-FET or 18F-FDG in a
lesion identified either in only one of them or on the CT and
verified as tumor in the USgFNAC. In addition, a clinical follow-up
for at least 6 months served as the standard of reference (12/13,
92%). A verified positive lymph node during follow-up, which was
not identified in the first session by either modality was labelled
false negative. In one case, the patient died 1 month after having
started an adequate therapy and therefore a follow-up for 6 months
was not possible. The ultrasound-guided fine needle aspiration was
always performed by the same specialist with a vast experience
regarding this staging method.
In summary, all numbers for sensitivity, specificity, and
accuracy are lesion based. Three lesions (two lesions suspicious
for a second primary and one lesion suspicious for a distant
metastasis) were initially not verified by cytology or histology. In
two of these cases, a clinical referral was able to exclude a second
primary, and in one patient a follow-up imaging examination
6 months later served as reference. All other patients with suspected
distant metastasis or secondary primaries distant from the neck
were referred for biopsy/cytology.
The tracer uptake in the lesions for both, the 18F-FET and the
18F-FDG scan, was visually graded as none, mild, moderate and
strong compared with background tissue. Mild, moderate, or strong
uptake was considered suspicious for tumor.
In addition to visual analysis, the uptake of 18F-FDG and 18F-
FET in the primary tumor was expressed as standardized uptake
values (SUV). For this purpose a region of interest (ROI) was
placed over the tumor using the image analysis software PMOD
(PMOD Technologies Ltd., Zurich, Switzerland). The ROI was
placed on the 18F-FDG or the 18F-FET scan, depending on where it
was best visible. It was then transferred to the other modality after
co-registration. To avoid any statistical noise, the mean uptake in
the ROI was chosen for reporting.
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Results
Between 2008 and 2009, the total number of 13 patients (11
males, two females) was evaluated with 18F-FDG PET/CT
and 18F-FET PET/CT for a previously untreated advanced
HNSCC. The mean age of the patients was 63.3 years
(range, 53–80 years), and the mean follow-up period of all
patients was 12.7 months (range, 1–22 months). One patient
could only be followed by a month because of death. All
other patients were followed for at least 6 months. Patient
information and tumor characteristics are shown in Table 1.
All patients presented in the advanced stages III and IV
(International Union against Cancer (UICC) 1997).
Positron Emission Tomography Imaging
Typical examples of 18F-FDG and 18F-FET PET scans are
illustrated in Figs. 1 and 2. Figure 1 demonstrates a patient
with moderate to strong 18F-FDG and 18F-FET uptake in the
primary tumor and the lymph node metastases with higher
tumor-to-background ratio in the 18F-FDG scan. In Fig. 2,
the primary tumor and the nodal disease are clearly visible
on the 18F-FDG scan, whereas all malignant lesions, except
the primary, are false negative on the 18F-FET scan. At
initial staging a total of 37 lesions were detected in the 13
patients (13 primaries and 24 lymph nodes). The primary
tumor was detected in all patients by 18F-FDG- and 18F-FET
PET/CT. The 18F-FDG uptake was rated “strong” in all
cases. The rating of the 18F-FET uptake was “strong” in
three patients, “moderate” in two cases and mild in eight
patients. At follow-up, 11 patients were available for 18F-
FDG and ten for 18F-FET imaging. The primary tumor site
uptake was rated “none” in all patients by using 18F-FET,
whereas with 18F-FDG, four primary tumor sites were rated
“mild”, one “moderate” and six were rated “none”.
With regard to lymph nodes suspicious findings on 18F-
FDG PET were found in 12 of the 13 patients (92%). The node
uptake was rated “moderate” or “strong”. In contrast, only
seven (54%) patients had suspicious nodes on 18F-FET PET,
the uptake in which was rated “mild” in six patients and
“strong” only in one patient. In summary, the lesion based rate
at initial staging for the primaries using 18F-FDG PET and 18F-
FET PET was 13 out of 13 (100%). With regard to the lymph
nodemetastases, the lesion based rate for 18F-FDG PETwas 20
out of 24 (83%), and 13 out of 24 (54%) for 18F-FET PET.
During follow-up, 18F-FDG PET was able to detect all three
histological confirmed local tumor persistences whereas 18F-
FET PET only detected two out of three and therefore missed
one true-positive lesion. With regard to the lymph node
metastases, the lesion based rate for 18F-FDG PET and for
18F-FET PET was two out of four (50%), respectively. The
calculated sensitivity and specificity for 18F-FDG and 18F-FET
are summarized in Table 2. The sensitivity to detect malig-
nancy was markedly higher for 18F-FDG than 18F-FET. The
specificity shows the reverse trend, at initial staging the
specificity of 18F-FET in suspicious lymph nodes was 90%
compared with only 50% for 18F-FDG. At follow-up, the
pattern is similar. The sensitivity data at follow-up are less
reliable due to the low number of true-positive lymph nodes.
There were five false-positive lymph nodes on 18F-FDG PET/
CT. All of these were cytologically confirmed as lymphadeni-
tis. On the contrary, 18F-FET PET/CT only detected one false-
positive finding that turned out to be an inflammatory enlarge-
ment of the lymph node. A different pattern was found in the
follow-up setting: 18F-FDG PET/CT revealed a total of two
false-positive primaries and a total of six false-positive lymph
nodes. The false-positive primaries histologically turned out to
be chronic inflammatory and fibrotic tissue. Regarding false-
positive lymph node metastases during follow-up, 18F-FDG
PET/CT revealed six lymph nodes which in the pathological
report turned out to be inflammatory and necrotic tissue. 18F-
FET PET/CT, on the contrary, did not reveal any false-positive
finding during follow-up resulting in a specificity of 100%.
Second Primaries and Distant Metastases
At initial staging, 18F-FDG PET/CT revealed a total of four
lesions suspicious for a second primary (one caecal, one
Table 1. Patient and tumor data
Patient nr Age Histologic grading Mitotic index (%) TU-subsite TNM-class UICC-stage
1 63 Moderate 30 Oropharynx T3 N0 M0 III
2 71 Poorly 50 Oropharynx T4 N1 M0 IV
3 66 Moderate 50 Oropharynx T4 N0 M1 IV
4 59 Poorly 80 Oropharynx T3 N1 M0 III
5 66 Poorly 50 Oral cavity T4 N1 M0 IV
6 52 Moderate 50 Oral cavity T4 N2c M0 IV
7 62 Poorly 90 Oropharynx T2 N2b M1 IV
8 80 Poorly 80 Oropharynx T4 N2b M0 IV
9 57 Moderate 5 Oropharynx T3 N0 M0 III
10 66 Moderate 60 Oropharynx T3 N1 M1 III
11 53 Poorly 25 Nasopharynx T3 N1 M0 III
12 73 Poorly 70 Oropharynx T3 N0 M0 III
13 55 Moderate 50 Oropharynx T4 N2c M1 IV
nr number, TU tumor, class classification, UICC international union against cancer
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gastric, one cutaneous, one prostate), and a total of three
lesions suspicious for distant metastases (all situated in the
lungs). The caecal lesion was confirmed as high-grade
dysplasia, and two pulmonary lesions were confirmed as
distant disease. In contrast, 18F-FET PET/CT detected only
two additional lesions suspicious for a lung metastasis, of
which one was confirmed as distant disease. The other
lesions detected by 18F-FDG PET/CT were not seen on the
18F-FET PET/CT scan.
At follow-up, 18F-FDG PET/CT, revealed two additional
findings suspicious for lung metastases. One was confirmed
histologically, and the second was confirmed radiologically
with follow-up scans. 18F-FET PET/CT detected one false-
positive caecal lesion (polypoid lesion with fibrotic tissue).
The work-up consisted of a biopsy. The two lung metastases
were not seen on 18F-FET PET/CT.
SUV Values at Initial Staging and after Therapy
in the Primary Tumor Site
The results of the ROI analysis are demonstrated in
Table 3. The mean SUV and the percentage reduction
after therapy were markedly higher for 18F-FDG than for
18F-FET. The average ROI SUV was also correlated with
the mitotic index and the grade of differentiation. The
18F-FDG SUV for the moderately differentiated tumors
Fig. 1. CT and PET examination at initial staging of a 55 years old male suffering from an oropharyngeal tumor, cT4 N2c cM1.
Transaxial contrast-enhanced CT and corresponding matched PET slices are presented in the top three rows, coronal PET
slices are demonstrated in the bottom two rows. The contrast-enhanced CT was taken at the same time as the FDG PET. Note
the higher tumor-to-background ratio in the FDG PET.
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was 16.8±6.4; whereas, for the poorly differentiated
tumors it was 11.5±4.1. However, the difference did not
reach statistical significance (student’s t test). For 18F-
FET, the corresponding numbers were 4.1±2.3 and 3.3±
1.1, respectively, not reaching statistical significance,
neither. Furthermore, no significant correlation was found
between the mitotic index and the 18F-FDG or 18F-FET
uptake.
Fig. 2. CT and PET examination at initial staging of a 80 years old patient suffering from a oropharyngeal tumor, cT4 cN2b cM0.
Transaxial low-dose CT and corresponding matched PET slices are presented in the top three rows, coronal PET slices are
demonstrated in the bottom two rows. The low-dose CT was acquired at the same time as the FDG PET. While the primary tumor and
the lymphnodemetastases are clearly visible on the FDGscan, allmalignant lesions, except the primary,were negative on the FET scan.
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Discussion
18F-FDG PET/CT has been shown to be a valuable tool in the
evaluation of patients with head and neck cancer. Regarding
the staging of nodal disease, recently published data empha-
sizes the value of 18F-FDG PET/CT at initial staging [9]. There
is also a role for 18F-FDG PET/CT in detecting second
primaries or distant metastases in patients with advanced
HNSCC [10, 11]. A major drawback of 18F-FDG PET/CT is
the relatively low specificity, which leads to a high number of
false-positive findings, especially after radiochemotherapy due
to the high 18F-FDG uptake in inflammatory cells, which may
be present after radiotherapy. This is reflected in the reduced
specificity for 18F-FDG in our study. Therefore, there is a need
for a tracer with higher specificity for tumor tissue. Based on
earlier studies 18F-FET seemed to be a good candidate. Kaim et
al. demonstrated in an abscess model in rats that 18F-FET does
not accumulate in inflammatory cells [4]. Other authors tested
the suitability of 18F-FET in human tumors: in their first study
of 18F-FET, Pauleit et al. looked at different tumor types (e.g.,
lymphoma, adenocarcinoma) originating at different sites of
the body (colorectal, pancreatic, lung, ovarian, breast, head,
and neck) [6]. In line with our study, they found a superior
specificity but a lower sensitivity of 18F-FET for the primary
tumor compared with 18F-FDG. They also reported that the
tumor-to-background contrast was significantly lower in 18F-
FET PET compared with 18F-FDGPET. This is in line with our
study (Figs. 1 and 2).
After concluding that the use of 18F-FET allows a better
distinction between tumors and inflammatory tissues in most
cases of SCC [6], Pauleit and his colleagues looked at HNSCC
only [7]: the sensitivity of 18F-FDG PET was 93%, the
specificity was 79%, and the accuracy was 83% compared
with 18F-FET PET with a sensitivity of 75%, a specificity of
95%, and an accuracy of 90%. In our study, we found the same
pattern, with 18F-FDG being more sensitive but less specific
than 18F-FET in the investigated tumors. As Pauleit stated a
potential benefit for 18F-FET PET in the follow-up of irradiated
patients [7], Balogova et al. looked also at 12 follow-up
patients [8]. As in our study, the good specificity of 18F-FET
was confirmed, but the sensitivity was insufficient. However,
they suggested, that in certain cases a wait and see strategymay
be chosen for an 18F-FDG-positive lesion if it is negative with
18F-FET. Compared with the previous studies by Pauleit et al.
[7] and Balogova et al. [8], it is the strength of this study to
confirm the previous findings in a more powerful way by
Table 2. Sensitivities, specificities, and accuracies of both modalities
Lesions True
positive
False
negative
True
negative
False
positive
Sensitivity (%) Specificity (%) PPV (%) NPV (%) Accuracy (%)
Initial staging FDG primary+lymph nodes 33 4 5 5 89 50 87 56 81
Initial staging FET primary+lymph nodes 26 11 9 1 70 90 96 45 74
Initial staging FDG lymph nodes 20 4 5 5 83 50 80 56 74
Initial staging FET lymph nodes 13 11 9 1 54 90 93 45 65
Follow-up FDG primary+lymph nodes 5 2 15 8 71 65 38 88 67
Follow-up FET primary+lymph nodes 2 5 23 0 29 100 100 82 83
Follow-up FDG lymph nodes 2 2 10 6 50 63 25 83 60
Follow-up FET lymph nodes 2 2 16 0 50 100 100 89 90
pos positive, neg negative
Table 3. SUV values and percentage decrease after therapy in the primary lesion
FDG1 FET1 FDG2 FET2 FDG decrease FET decrease
SUV SUV SUV SUV % of FDG1 % of FET1
Patient nr
1 25.07 3.51 3.74 2.03 85.09 42.21
2 18.24 3.45 3.92 1.87 78.52 45.82
3 22.46 8.51 3.51
4 10.70 3.24 3.83 3.04 64.21 6.29
5 13.23 5.40
6 19.16 2.30
7 10.04 3.27 2.77 1.95 72.35 40.39
8 14.35 3.03 2.61 2.38 81.81 21.44
9 12.56 4.15 3.90 1.75 68.95 57.80
10 8.52 2.46 1.68 1.61 80.22 34.30
11 7.44 1.72 1.22 1.31 83.61 23.37
12 6.44 2.90 3.80 1.78 40.92 38.56
13 13.23 3.67 2.14 1.66 83.83 54.81
Mean 13.96 3.66 3.01 1.94 73.95 36.50
SD 5.77 1.71 0.98 0.48 13.54 15.79
COV 41.31 46.75 32.59 24.63 18.31 43.27
SUV standardized uptake value, nr number, SD standard deviation, COV coefficient of variation (SD/mean*100)
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intra-individual comparison. The loss of information was
therefore kept to a minimum by analysing the data of the same
patients undergoing both imaging modalities at initial staging
and during follow-up. Another advantage of this study design
is the comparison of the variation of the SUVs of 18F-FDG and
18F-FET before/after treatment and therefore the response to
treatment.
After all, in daily practice of managing patients with
HNSCC it is worse missing a true-positive lesion than
detecting a false-positive one since suspicious lesions can
always be further evaluated by fine needle puncture or
biopsy, whereas missed tumors may grow into incurable
disease. After having looked at the size of the false
negatives, the range of the lesion size was between 1.2 and
3.5 cm. Given the 0.5 cm resolution of the used PET/CT
system, the size of the lesion was therefore not a reason for
the false-negative lesions revealed by 18F-FET. In addition,
18F-FDG PET/CT detected a higher number of second
malignancies or distant metastases compared with 18F-FET
PET/CT. In our practice, we will continue to use 18F-FDG
PET/CT for advanced disease routinely, as these additional
findings heavily affect the management of the patient. Some
question may arise regarding the reliability of sensitivities
and specificities presented in this paper, due to the relatively
low number of patients. However, the number of lesions
used to calculate the figures should be sufficient yield a
useful estimate. Furthermore, the numbers are in good
agreement with earlier published data [8].
As mentioned above, there is another argument favouring
18F-FDG based on our intra-individual analysis: the SUV
measurements in the primary tumor were considerably
higher for 18F-FDG leading to a higher tumor-to-background
ratio (the SUV values at follow-up represent more or less
background), which may partially be responsible for the
higher sensitivity. Furthermore, 18F-FET demonstrated a
much smaller post-therapeutic percentage reduction com-
pared with 18F-FDG, reducing its suitability for the evalua-
tion of a treatment. A limitation of this study is that not all
patients received a contrast-enhanced CT at the time of PET
scanning. It is therefore possible, that some tumorous lesions
may have been missed which would have increased the
false-negative number for 18F-FET and 18F-FDG. However,
given the high sensitivity of 18F-FDG and the fact that most
patients were scanned twice, the number of such missed
tumorous lesions can be expected to be small. The 18F-FDG
scan was performed 45 min following injection. Other
centers use a 60 min uptake time, which potentially
increases the tumor-to-background ratio. However, since
the 18F-FDG uptake in the positive lesions was clearly
visible at 45 min, it is unlikely that our results would have
changed with a 60 min uptake time.
Conclusion
This study delivers further evidence that 18F-FET is no
substitute for 18F-FDG in the initial staging or follow-up of
patients with HNSCC. Although it is more specific, too
many malignant lesions are missed due to its lower
sensitivity.
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